C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/48 (2006.01) G01N 33/574 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2598185
The invention is directed at a method for predicting a patient's responsiveness to a CHK1 inhibitor. The method includes providing a sample from a test patient who is being treated with a DNA damaging agent; and determining for the presence of an activated CHK1 signal transduction pathway molecule, wherein the presence of an activated CHK1 signal transduction pathway molecule is indicative that a CHK1 inhibitor should be administered to the patient.
L'invention concerne un procédé permettant de prévoir la sensibilité d'un patient à un inhibiteur de la CHK1. Ce procédé consiste à obtenir un prélèvement d'un patient d'essai traité à l'aide d'un agent endommageant l'ADN, puis à déterminer la présence d'une molécule de la voie de transduction du signal de la CHK1 activée, la présence d'une molécule de la voie de transduction du signal de la CHK1 activée indiquant qu'un inhibiteur de la CHK1 devrait être administré au patient.
Bergeron Louise
Zabludoff Sonya
Astrazeneca Ab
Fetherstonhaugh & Co.
LandOfFree
Method for determining responsiveness to chk1 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for determining responsiveness to chk1 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for determining responsiveness to chk1 inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2024831